Retrospective analysis of immunosuppressive and anti-thrombotic protocols in nonassociative immune mediated hemolytic anemia in dogs
Journal of Veterinary Internal Medicine · 2023
DOI: 10.1111/jvim.16652 ↗At a glance
Multizentrische Studie in Journal of Veterinary Internal Medicine, 2023. Written by Jennifer Weng and 7 co-authors. Institution: Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan 48824, USA. Major MEDLINE topics: Anemia, Hemolytic, Anemia, Hemolytic, Autoimmune, Dog Diseases. Cited 7 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
Evidence supporting the effectiveness of therapeutic protocols for nonassociative immune-mediated hemolytic anemia (na-IMHA) is weak. Hypothesis/Objectives Investigate the efficacy of various drugs in na-IMHA. Animals Two hundred forty-two dogs.
Methods
Multi-institutional retrospective study (2015-2020). Immunosuppressive effectiveness was determined by time to packed cell volume (PCV) stabilization and duration of hospitalization through analysis by mixed model linear regression. Occurrence of disease relapse, death, and antithrombotic effectiveness, were analyzed using mixed model logistic regression.
Results
Use of corticosteroids vs a multi-agent protocol had no effect on time to PCV stabilization (P = .55), duration of hospitalization (P = .13), or case fatality (P = .06). A higher rate of relapse (P = .04; odds ratio: 3.97; 95% confidence interval [CI]: 1.06-14.8) was detected in dogs receiving corticosteroids (11.3%) during follow-up (median: 28.5 days, range: 0-1631 days) compared to multiple agents (3.1%) during follow up (median: 47.0 days, range: 0-1992 days). When comparing drug protocols, there was no effect on time to PCV stabilization (P = .31), relapse (P = .44), or case fatality (P = .08). Duration of hospitalization was longer, by 1.8 days (95% CI: 0.39-3.28 days), for the corticosteroid with mycophenolate mofetil group (P = .01) compared to corticosteroids alone. Use of clopidogrel vs multiple agents had no effect on development of thromboses (P ≥ .36). Conclusions and Clinical Importance Addition of a second immunosuppressive agent did not alter immediate outcome measures but might be associated with a reduction in relapse. Use of multiple antithrombotic agents did not reduce incidence of thrombosis.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan 48824, USA.
- Department of Pathobiology and Population Medicine, College of Veterinary Medicine, Mississippi State University, Mississippi State, Mississippi 39762, USA.
- Department of Clinical Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi State, Mississippi 39762, USA.
ORCID profiles: Andrew J Mackin, John M Thomason, Harry Cridge
Cite
APA
Weng, J., Levy, N. A., Abbott, H. Y., Mix, J. A., Wills, R. W., Mackin, A. J., Thomason, J. M., & Cridge, H. (2023). Retrospective analysis of immunosuppressive and anti-thrombotic protocols in nonassociative immune mediated hemolytic anemia in dogs. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.16652
Vancouver
Weng J, Levy NA, Abbott HY, Mix JA, Wills RW, Mackin AJ, et al. Retrospective analysis of immunosuppressive and anti-thrombotic protocols in nonassociative immune mediated hemolytic anemia in dogs. Journal of Veterinary Internal Medicine. 2023. doi:10.1111/jvim.16652
BibTeX
@article{Weng2023,
author = {Weng, Jennifer and Levy, Nyssa A and Abbott, Haley Y and Mix, Jose A and Wills, Robert W and Mackin, Andrew J and Thomason, John M and Cridge, Harry},
title = {Retrospective analysis of immunosuppressive and anti-thrombotic protocols in nonassociative immune mediated hemolytic anemia in dogs},
journal = {Journal of Veterinary Internal Medicine},
year = {2023},
doi = {10.1111/jvim.16652}
}
EUVIMED